A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy (AIO-STO-0111)
A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen
Sponsor: Krankenhaus Nordwest
A PHASE3 clinical study on Advanced Gastric Cancer and Esophagogastric Junction Cancer, this trial is completed. The trial is conducted by Krankenhaus Nordwest and has accumulated 10 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Sep 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
-
Apr 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Krankenhaus Nordwest
For direct contact, visit the study record on ClinicalTrials.gov .